Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$2.55 +8.5%	$2.69	$2.12 ▼ $5.80	$253.29M	2.02	1.52 million shs	1.39 million shs
BMEA Biomea Fusion	$1.42 -4.1%	$1.90	$1.36 ▼ $13.07	$53.35M	-0.07	908,455 shs	818,105 shs
ITOS iTeos Therapeutics	$8.53 -0.4%	$6.79	$4.80 ▼ $18.13	$326.48M	1.39	571,202 shs	969,530 shs
MBX MBX Biosciences	$12.60 +3.7%	$9.10	$4.81 ▼ $27.50	$421.14M	N/A	252,089 shs	191,203 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+8.51%	+6.69%	-11.15%	-7.27%	-16.67%
BMEA Biomea Fusion	-4.05%	-9.55%	-35.16%	-50.00%	-87.09%
ITOS iTeos Therapeutics	-0.35%	+2.16%	+16.05%	+20.65%	-51.75%
MBX MBX Biosciences	+3.70%	+1.94%	+37.40%	+26.00%	+1,259,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	1.2739 of 5 stars	3.5	2.0	2.0	0.0	0.0
BMEA Biomea Fusion	2.4102 of 5 stars	3.5	0.0	2.2	3.3	1.3
ITOS iTeos Therapeutics	3.2547 of 5 stars	4.2	1.0	3.5	3.3	0.6
MBX MBX Biosciences	2.8014 of 5 stars	3.5	0.0	2.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$10.67	318.30% Upside
BMEA Biomea Fusion	3.08	Buy	$22.60	1,491.55% Upside
ITOS iTeos Therapeutics	2.43	Hold	$17.86	109.35% Upside
MBX MBX Biosciences	3.00	Buy	$37.50	197.62% Upside

Current Analyst Ratings Breakdown

Latest BMEA, MBX, AQST, and ITOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/15/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/14/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $13.00
5/14/2025	ITOS iTeos Therapeutics	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
5/14/2025	ITOS iTeos Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $12.00
5/14/2025	ITOS iTeos Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/14/2025	ITOS iTeos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/14/2025	ITOS iTeos Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$47.00 ➝ $9.00
5/13/2025	ITOS iTeos Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$15.00 ➝ $8.00
5/6/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00
5/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$54.23M	4.67	N/A	N/A	($1.59) per share	-1.60
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$4.74 per share	N/A
ITOS iTeos Therapeutics	$35M	9.33	N/A	N/A	$16.08 per share	0.53
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$7.87M	-$0.59	N/A	N/A	N/A	-59.75%	N/A	-33.96%	8/5/2025 (Estimated)
BMEA Biomea Fusion	-$117.25M	-$3.55	N/A	N/A	N/A	N/A	-118.90%	-93.66%	7/30/2025 (Estimated)
ITOS iTeos Therapeutics	-$112.64M	-$3.04	N/A	N/A	N/A	N/A	-20.11%	-17.50%	8/14/2025 (Estimated)
MBX MBX Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest BMEA, MBX, AQST, and ITOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million
5/5/2025	Q1 2025	BMEA Biomea Fusion	-$0.84	-$0.80	+$0.04	-$0.80	N/A	N/A
4/28/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	-$0.80	+$0.14	-$0.80	$9.35 million	N/A
3/31/2025	Q4 2024	BMEA Biomea Fusion	-$1.00	-$0.81	+$0.19	-$0.81	N/A	N/A
3/5/2025	Q4 2024	AQST Aquestive Therapeutics	-$0.14	-$0.19	-$0.05	-$0.19	$13.11 million	$11.87 million
3/5/2025	Q4 2024	ITOS iTeos Therapeutics	-$1.14	-$1.01	+$0.13	-$1.01	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	6.37	5.91
BMEA Biomea Fusion	N/A	3.39	3.39
ITOS iTeos Therapeutics	N/A	14.80	14.80
MBX MBX Biosciences	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
BMEA Biomea Fusion	96.72%
ITOS iTeos Therapeutics	97.16%
MBX MBX Biosciences	N/A

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	8.35%
BMEA Biomea Fusion	27.57%
ITOS iTeos Therapeutics	12.50%
MBX MBX Biosciences	52.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.33 million	84.02 million	Optionable
BMEA Biomea Fusion	50	37.57 million	26.25 million	Optionable
ITOS iTeos Therapeutics	90	38.27 million	31.97 million	Optionable
MBX MBX Biosciences	36	33.42 million	N/A	N/A

BMEA, MBX, AQST, and ITOS Headlines

Recent News About These Companies

Woodline Partners LP Buys 89,046 Shares of MBX Biosciences, Inc. (NYSE:MBX)

May 25 at 4:41 AM | marketbeat.com

Citadel Advisors LLC Grows Stock Holdings in MBX Biosciences, Inc. (NYSE:MBX)

May 21, 2025 | marketbeat.com

MBX Biosciences to Participate in June Investor Conferences

May 20, 2025 | globenewswire.com

Parkman Healthcare Partners LLC Purchases New Shares in MBX Biosciences, Inc. (NYSE:MBX)

May 16, 2025 | marketbeat.com

MBX Biosciences, Inc.: Strong Buy Rating Amid Promising Phase II Data and Robust Financial Position

May 13, 2025 | tipranks.com

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 12, 2025 | globenewswire.com

Driehaus Capital Management LLC Acquires 600,438 Shares of MBX Biosciences, Inc. (NYSE:MBX)

May 11, 2025 | marketbeat.com

FESM's Underlying Holdings Could Mean 34% Gain Potential

May 10, 2025 | nasdaq.com

MBX Biosciences, Inc. (NYSE:MBX) Stake Lessened by Alyeska Investment Group L.P.

May 9, 2025 | marketbeat.com

Schonfeld Strategic Advisors LLC Purchases New Position in MBX Biosciences, Inc. (NYSE:MBX)

May 9, 2025 | marketbeat.com

MBX Biosciences, Inc. (NYSE:MBX) Receives Consensus Rating of "Buy" from Analysts

May 6, 2025 | marketbeat.com

MBX Biosciences, Inc. (NYSE:MBX) Shares Sold by Price T Rowe Associates Inc. MD

May 4, 2025 | marketbeat.com

MBX Biosciences, Inc. (NYSE:MBX) Shares Purchased by Geode Capital Management LLC

April 28, 2025 | marketbeat.com

Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth

April 23, 2025 | finance.yahoo.com

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

April 22, 2025 | globenewswire.com

Ascendis Pharma initiated with an Outperform at RBC Capital

April 16, 2025 | markets.businessinsider.com

JMP Securities Initiates Coverage of MBX Biosciences (MBX) with Market Outperform Recommendation

April 11, 2025 | msn.com

Ora H. Pescovitz Buys 7,693 Shares of MBX Biosciences, Inc. (NYSE:MBX) Stock

April 11, 2025 | insidertrades.com

MBX Biosciences initiated with an Outperform at Citizens JMP

April 10, 2025 | markets.businessinsider.com

MBX Biosciences adds biotech veteran to board

April 9, 2025 | uk.investing.com

MBX Biosciences appoints Steve Hoerter to board of directors

April 8, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA, MBX, AQST, and ITOS Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$2.55 +0.20 (+8.51%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$2.54 -0.01 (-0.59%)

As of 05/27/2025 07:37 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Biomea Fusion NASDAQ:BMEA

$1.42 -0.06 (-4.05%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$1.44 +0.02 (+1.41%)

As of 05/27/2025 07:19 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

iTeos Therapeutics NASDAQ:ITOS

$8.53 -0.03 (-0.35%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$8.53 0.00 (0.00%)

As of 05/27/2025 04:04 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

MBX Biosciences NYSE:MBX

$12.60 +0.45 (+3.70%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$11.92 -0.68 (-5.40%)

As of 05/27/2025 05:35 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time